JC
RCUS icon

JBF Capital’s Arcus Biosciences RCUS Stock Holding History

JBF Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,712
Closed -$80K – 130
2018
Q3 		$80K Sell
5,712
-23,537
-80% -$300K 0.01% 81
2018
Q2 		$358K Sell
29,249
-70,751
-71% -$1.11M 0.05% 60
2018
Q1 		$1.54M Buy
+100,000
New +$1.67M 0.24% 27

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JBF Capital's RCUS Position: Q4 2018 in Review

JBF Capital sold out of Arcus Biosciences (RCUS) in Q4 2018, closing a stake of 5,712 shares — an estimated $80K sold.

JBF Capital first reported a position in RCUS in Q1 2018 and held it in 3 quarters. The position peaked at $1.54M in Q1 2018. 67 funds tracked by Wall St. Rank hold RCUS as of Q4 2018.

  • JBF Capital reported no remaining Arcus Biosciences position as of Q4 2018 after selling out during the quarter.
  • JBF Capital sold 5,712 Arcus Biosciences shares in Q4 2018, an estimated $80K.
  • JBF Capital first reported a position in Arcus Biosciences in Q1 2018 and held it in 3 quarters.
  • JBF Capital's Arcus Biosciences position peaked at $1.54M in Q1 2018.
  • 67 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.